| pubmed-article:2965725 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0024348 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:2965725 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:2965725 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:2965725 | pubmed:dateCreated | 1988-5-18 | lld:pubmed |
| pubmed-article:2965725 | pubmed:abstractText | The present study was undertaken to determine whether human PBL can be specifically focused to lyse cells infected with HIV-1 by mAb heteroconjugates that can bridge target and effector cells. A mAb directed against the central portion of HIV-1 glycoprotein gp110 was chemically cross-linked to a mAb directed against the CD3/TCR complex or to a mAb directed against the CD16 Fc gamma-R expressed on large granular lymphocytes (LGL). HIV-1-infected cells, but not uninfected cells, were found to be lysed to a greater extent by PBL in the presence of the gp110 X CD3 or the gp110 X CD16 antibody heteroconjugate than in the presence of the single antibodies or a mixture of the mAb comprising the heteroconjugates. Pretreatment of PBL with anti-CD3 or IL-2 augments their ability to lyse HIV-1-infected cells in the presence of the heteroconjugates. Lysis by anti-CD3-activated PBL in the presence of the gp110 X CD3 heteroconjugate was found to be mediated by CD8+-enriched T cells, whereas lysis by IL-2-treated PBL in the presence of the gp110 X CD16 heteroconjugate is mediated by PBL enriched for CD16+ cells, which are primarily LGL. Furthermore, PBL from asymptomatic, HIV-1-infected seropositive donors were found to be functional in lysing HIV-1-infected cells in the presence of the antibody heteroconjugates. Such antibody heteroconjugates, which can target T cells or LGL to lyse HIV-1-infected cells, may be of prophylactic or therapeutic value in HIV-1-infected individuals. | lld:pubmed |
| pubmed-article:2965725 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2965725 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2965725 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2965725 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2965725 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:2965725 | pubmed:author | pubmed-author:ZarlingJ MJM | lld:pubmed |
| pubmed-article:2965725 | pubmed:author | pubmed-author:McClureJJ | lld:pubmed |
| pubmed-article:2965725 | pubmed:author | pubmed-author:ShriverKK | lld:pubmed |
| pubmed-article:2965725 | pubmed:author | pubmed-author:LedbetterJ... | lld:pubmed |
| pubmed-article:2965725 | pubmed:author | pubmed-author:MoranP APA | lld:pubmed |
| pubmed-article:2965725 | pubmed:author | pubmed-author:GrosmaireL... | lld:pubmed |
| pubmed-article:2965725 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2965725 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2965725 | pubmed:volume | 140 | lld:pubmed |
| pubmed-article:2965725 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2965725 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2965725 | pubmed:pagination | 2609-13 | lld:pubmed |
| pubmed-article:2965725 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:meshHeading | pubmed-meshheading:2965725-... | lld:pubmed |
| pubmed-article:2965725 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2965725 | pubmed:articleTitle | Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates. | lld:pubmed |
| pubmed-article:2965725 | pubmed:affiliation | Oncogen, Seattle, WA 98121. | lld:pubmed |
| pubmed-article:2965725 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2965725 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2965725 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2965725 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2965725 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2965725 | lld:pubmed |
